EZH2 as a Regulator of CD8+T Cell Fate and Function

被引:30
|
作者
Stairiker, Christopher J. [1 ]
Thomas, Graham D. [1 ]
Salek-Ardakani, Shahram [1 ]
机构
[1] Pfizer Inc, Canc Immunol Discovery, Worldwide Res Dev & Med, San Diego, CA 92121 USA
来源
FRONTIERS IN IMMUNOLOGY | 2020年 / 11卷
关键词
EZH2; enhancer of zeste homolog 2; CD8 lymphocytes plus; effector; memory; cell fate and differentiation; virus; cancer; CD8(+) T-CELLS; EPIGENETIC LANDSCAPE; EFFECTOR; DIFFERENTIATION; METHYLATION; ACTIVATION; EXPRESSION; ANTIGEN; TRANSCRIPTION; TRAFFICKING;
D O I
10.3389/fimmu.2020.593203
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Enhancer of zeste 2 (EZH2) is the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) that mediates di- and trimethylation of histone 3 lysine 27 effectively precluding successful gene transcription at these loci. This class of epigenetic modifications facilitates the maintenance of tissue-specific cellular transcriptional programs as cells undergoing successive rounds of proliferation. CD8+ T cells are effective mediators of adaptive immunity and function to eliminate virus- and bacteria-infected cells as well as tumor cells. Upon recognition of cognate antigen, T cells undergo activation/proliferation to clear the target cells. The heterogeneous population of responding T cells formed during these proliferative events thus rely on epigenetic modifications to ensure identity and confer functional capabilities. In this review, we will focus on the role of the dynamic expression EZH2 in shaping the epigenetic landscape of CD8+ T cell fate and function, with a particular emphasis on infection and cancer. We also explore competing hypotheses pertaining to EZH2 function and the prospects of clinical EZH2 inhibitors in fine-tuning T cell responses.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] CD8+T cell response to polycomb protein EZH2 in haemopoietic malignancies
    Kalk, E
    Piper, K
    Pratt, G
    Young, L
    Steele, J
    Moss, P
    IMMUNOLOGY, 2005, 116 : 48 - 49
  • [2] CD8+T cell responses to the polycomb protein EZH2 in patients with haemopoietic malignancies.
    Kalk, E
    Piper, K
    Pratt, G
    Young, L
    Steele, J
    Moss, P
    BLOOD, 2005, 106 (11) : 59B - 59B
  • [3] Regulation and roles of polyamines in CD8+T cell fate and function
    Elmarsafawi, Aya G.
    Hesterberg, Rebecca S.
    Cleveland, John L.
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Regulation of T Cell Differentiation and Function by EZH2
    Karantanos, Theodoros
    Chistofides, Anthos
    Barhdan, Kankana
    Li, Lequn
    Boussiotis, Vassiliki A.
    FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [5] microRNAs function in CD8+T cell biology
    Liang, Yan
    Pan, Hai-Feng
    Ye, Dong-Qing
    JOURNAL OF LEUKOCYTE BIOLOGY, 2015, 97 (03) : 487 - 497
  • [6] Epigenetic control during CD8+T cell fate commitment
    Pace, L.
    Goudot, C.
    Zueva, E.
    Gueguen, P.
    Burgdorf, N.
    Waterfall, J. J.
    Quivy, J. -P.
    Almouzni, G.
    Amigorena, S.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 707 - 707
  • [7] EZH2: a pivotal regulator in controlling cell differentiation
    Chen, Ya-Huey
    Hung, Mien-Chie
    Li, Long-Yuan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2012, 4 (04): : 364 - 375
  • [8] Coupling metabolic activities to regulate CD8+T cell differentiation and fate
    Shrikant, Protul A.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [9] Uncovering the role of STAT5 in CD8+T cell fate
    Chanda, Monica Kasturi
    Gu, Zehui
    Piper, Taylor L.
    Shudde, Claire E.
    Courtney, Adam H.
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [10] Arginase-2 serves as an immunometabolic checkpoint regulator of anti-tumor CD8+T cell function and persistence
    Marti i Lindez, A. A.
    Dunand-Sauthier, I.
    Conti, M.
    Nunez, N.
    Becher, B.
    Hannich, J. T.
    Riezman, H.
    Hugues, S.
    Reith, W.
    SWISS MEDICAL WEEKLY, 2019, : 25S - 25S